Acute Myeloid Leukemia (AML) Clinical Trial
Official title:
A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
The purpose of this study is to test the safety of selinexor (KPT-330) and to find the
highest dose of selinexor (KPT-330) that can be given safely when it is combined with two
chemotherapy drugs (fludarabine and cytarabine). This study will be done in two parts: Phase
I and Phase II.
The goal of Phase I is to find the highest tolerable dose of selinexor (KPT-330) that we can
give to patients with leukemia or MDS, when it is combined with fludarabine and cytarabine.
The goal of the subsequent Phase II portion of the study (insert NCT ID of SELHEM-2) is to
give the highest dose of selinexor (KPT-330) in combination with fludarabine/cytarabine that
was found in Phase I to be safe for children with leukemia or MDS. The investigators will
examine the effect of this combination treatment.
PRIMARY OBJECTIVE:
- Determine a tolerable combination of selinexor, fludarabine, and cytarabine in pediatric
patients with relapsed or refractory hematologic malignancies included acute myeloid
leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia
(MPAL) and myelodysplastic syndrome (MDS).
SECONDARY OBJECTIVES:
- To characterize the pharmacokinetics of selinexor, when administered in tablet form,
after the first dose and at steady-state, as well as in combination with fludarabine and
cytarabine
- To estimate the overall response rate of selinexor given with fludarabine and cytarabine
in patients with relapsed or refractory hematologic malignancies
Phase I will characterize the dose-limiting toxicities (DLTs) and determine the maximum
tolerated dose (MTD) or recommended phase II dose of selinexor when given in combination with
fludarabine and cytarabine.
Selinexor will be given twice weekly (on days 1 and 3) and escalated or de-escalated based on
tolerability. The rolling-6 design will be used for this study. Only cycle 1 of therapy will
be used to evaluate the DLT. Two to six participants can be concurrently enrolled onto a dose
level, dependent on 1) the number of participants enrolled at the current dose level, 2) the
number of participants who have experienced DLT at the current dose level, and 3) the number
of participants entered but with tolerability data pending at the current dose level. Accrual
is suspended when a cohort of six has enrolled or when the study endpoints have been met.
Once the recommended Phase II dose is determined, additional patients will be enrolled, if
necessary, so that at least 6 subjects are treated with the recommended Phase II dose to
determine MTD. After the MTD is determined, 12 additional patients will be treated at this
dose level for further evaluation of tolerability and response.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04240002 -
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
| Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
| Completed |
NCT05488613 -
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
|
||
| Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT02927938 -
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
|
Phase 3 | |
| Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
| Recruiting |
NCT03188874 -
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
|
||
| Completed |
NCT00071006 -
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Completed |
NCT04079296 -
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/Phase 2 | |
| Completed |
NCT04509622 -
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
|
Phase 3 | |
| Withdrawn |
NCT03699384 -
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
| Completed |
NCT02252107 -
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
|
Phase 2 | |
| Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
| Terminated |
NCT01463410 -
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
|
N/A | |
| Completed |
NCT01242774 -
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Terminated |
NCT02134782 -
Yoga Fatigue Study
|
N/A | |
| Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
| Completed |
NCT03625505 -
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT04266795 -
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
|
Phase 2 |